Poxel S.A. (LON:0RA2)
0.2840
-0.0170 (-5.65%)
At close: Feb 11, 2026
Poxel Revenue
Poxel had revenue of 2.18M EUR in the half year ending June 30, 2025, with 128.59% growth. This brings the company's revenue in the last twelve months to 7.66M, up 249.95% year-over-year. In the year 2024, Poxel had annual revenue of 6.64M with 234.98% growth.
Revenue (ttm)
7.66M EUR
Revenue Growth
+249.95%
P/S Ratio
2.01
Revenue / Employee
1.53M EUR
Employees
5
Market Cap
13.20M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.64M | 4.66M | 234.98% |
| Dec 31, 2023 | 1.98M | 1.31M | 193.92% |
| Dec 31, 2022 | 674.00K | -12.72M | -94.97% |
| Dec 31, 2021 | 13.40M | 6.59M | 96.84% |
| Dec 31, 2020 | 6.81M | -19.75M | -74.37% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Futura Medical | 7.93M |
| IXICO | 6.53M |
| Arecor Therapeutics | 5.06M |
| Fusion Antibodies | 1.60M |
| Aptamer Group | 1.20M |
| OptiBiotix Health | 1.15M |
| Oxford BioDynamics | 1.10M |
| CRISM Therapeutics | 25.00K |